A new order in BTK inhibition
Imbruvica faces challenges on multiple fronts.
ASH 2023 movers – an unexpected comeback for MorphoSys
MorphoSys, Blueprint and Syndax celebrate a successful ASH; Cogent not so much.
ASH 2023 – the markets forgive MorphoSys
Competitors struggle, while MorphoSys investors see a path forward for pelabresib after all.
